Cannabinoid CB 1 receptors regulate neuronal TNF-a effects in experimental autoimmune encephalomyelitis

a Neurologic Clinic, Department of Neuroscience, Tor Vergata University, 00133 Rome, Italy b Santa Lucia Foundation/Centro Europeo per la Ricerca sul Cervello (CERC), 00143 Rome, Italy c Neuroimmunology Unit-DIBIT, INspE, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy d Skaggs Institute for Chemical Biology and Department of Cell Biology, The Scripps Research Institute, North Torrey Pines Road, La Jolla, CA 92037, USA e Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, 55128 Mainz, Germany f Dipartimento di Scienze Biomediche, Università degli Studi di Teramo, 64100 Teramo, Italy

[1]  D. Centonze,et al.  The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis , 2011, Multiple sclerosis.

[2]  D. Centonze,et al.  Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis , 2010, Brain, Behavior, and Immunity.

[3]  D. Centonze,et al.  The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis , 2010, Experimental Neurology.

[4]  M. Lynch,et al.  Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis , 2010, Brain, Behavior, and Immunity.

[5]  E. Beattie,et al.  Cannabinoid receptor activation reduces TNFα-Induced surface localization of AMPAR-type glutamate receptors and excitotoxicity , 2010, Neuropharmacology.

[6]  C. Tench,et al.  Plasma endocannabinoid levels in multiple sclerosis , 2009, Journal of the Neurological Sciences.

[7]  Alessandro Martorana,et al.  Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis , 2009, Neurobiology of Disease.

[8]  Guozhi Tao,et al.  Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry , 2009, Journal of the Neurological Sciences.

[9]  D. Centonze,et al.  Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.

[10]  R. Tuma,et al.  Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke , 2009, Journal of Neuroimmune Pharmacology.

[11]  J. Borrell,et al.  A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules , 2009, Molecular and Cellular Neuroscience.

[12]  J. Ma,et al.  Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis , 2008, Neuroscience Letters.

[13]  K. Mackie,et al.  Wiring and firing neuronal networks: endocannabinoids take center stage , 2008, Current Opinion in Neurobiology.

[14]  N. Davoust,et al.  The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. , 2008, The Journal of biological chemistry.

[15]  M. García-Arencibia,et al.  Role of CB2 receptors in neuroprotective effects of cannabinoids , 2008, Molecular and Cellular Endocrinology.

[16]  D. Centonze,et al.  Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum , 2008, Nature Neuroscience.

[17]  C. Ledent,et al.  Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis , 2008, Journal of Neuroimmunology.

[18]  G. Martino,et al.  Multifaceted aspects of inflammation in multiple sclerosis: The role of microglia , 2007, Journal of Neuroimmunology.

[19]  Mauro Maccarrone,et al.  The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. , 2007, Brain : a journal of neurology.

[20]  R. Mutani,et al.  Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage , 2007, Journal of neuropathology and experimental neurology.

[21]  C. Herron,et al.  A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus , 2007, Neuropharmacology.

[22]  C. Ledent,et al.  Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells , 2007, Nature Medicine.

[23]  Beat Lutz,et al.  The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus , 2006, Neuron.

[24]  Vivien Chevaleyre,et al.  Endocannabinoid-mediated synaptic plasticity in the CNS. , 2006, Annual review of neuroscience.

[25]  Cai Song,et al.  Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons , 2006, Journal of Neuroimmunology.

[26]  Michal Schwartz,et al.  Microglial phenotype: is the commitment reversible? , 2006, Trends in Neurosciences.

[27]  C. Guaza,et al.  Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Mauro Maccarrone,et al.  Abnormal Sensitivity to Cannabinoid Receptor Stimulation Might Contribute to Altered Gamma-Aminobutyric Acid Transmission in the Striatum of R6/2 Huntington’s Disease Mice , 2005, Biological Psychiatry.

[29]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[30]  Daniel Pelletier,et al.  Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. , 2005, Brain : a journal of neurology.

[31]  R. Malenka,et al.  Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α , 2005, The Journal of Neuroscience.

[32]  M. Valenti,et al.  Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis , 2005, Journal of neurochemistry.

[33]  N. Stella,et al.  Cannabinoids and neuroinflammation , 2004, British journal of pharmacology.

[34]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[35]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[36]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[37]  J. Borrell,et al.  Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.

[38]  Rohit Bakshi,et al.  Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study , 2003, Neuroreport.

[39]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[40]  M. Beltramo,et al.  Cannabinoids and neuroprotection , 2001, Molecular Neurobiology.

[41]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. Hsu,et al.  Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.

[43]  A. Pérez-Samartín,et al.  The link between excitotoxic oligodendroglial death and demyelinating diseases , 2001, Trends in Neurosciences.

[44]  T. Olsson,et al.  Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis , 2000, Journal of Neuroimmunology.

[45]  C. Bolton,et al.  MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. , 1997, The Journal of pharmacology and experimental therapeutics.

[46]  T. Olsson,et al.  Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis , 1996, Journal of the Neurological Sciences.

[47]  R. Mechoulam,et al.  Suppression of experimental autoimmune encephalomyelitis by cannabinoids. , 1994, Immunopharmacology.

[48]  M. Herkenham,et al.  The cannabinoid receptor: biochemical, anatomical and behavioral characterization , 1990, Trends in Neurosciences.

[49]  J. Martín,et al.  Patterns of disease activity in multiple sclerosis. , 1990, BMJ.

[50]  C. Brosnan,et al.  Δ 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis , 1989, Journal of Neuroimmunology.

[51]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[52]  D. Lovinger.  Presynaptic modulation by endocannabinoids. , 2008, Handbook of experimental pharmacology.

[53]  P. McDonald,et al.  Brain, Behavior and Immunity in Cancer , 2008 .

[54]  R. Malenka,et al.  Synaptic scaling mediated by glial TNF-alpha. , 2006, Nature.

[55]  N. Mitsuma,et al.  Production of interferon-gamma by microglia. , 2006, Multiple sclerosis.

[56]  S. Miller,et al.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. , 2003, The Journal of clinical investigation.

[57]  K. Nékám,et al.  Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis. , 2003, Acta microbiologica et immunologica Hungarica.

[58]  D. Lovinger,et al.  CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.

[59]  L. Turski,et al.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.

[60]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[61]  T. Bisogno,et al.  The FASEB Journal express article 10.1096/fj.00-0399fje. Published online December 8, 2000. Endocannabinoids control spasticity in a multiple sclerosis model , 2022 .